HIMS
HIMS
US4330001060
Hims & Hers Health, Inc.
Loading chart...

Company Profile

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

Latest News

Related stocks

ELAN
ELAN • United States
Elanco Animal Health Incorporat
22.92 USD
11.45B USD 1Y +10.8%
AMRX
AMRX • United States
Amneal Pharmaceuticals, Inc.
19.91 USD
6.93B USD 1Y +87.5%
CURA.TO
CURA.TO • United States
CURALEAF HOLDINGS INC
13.31 CAD
2.47B USD 1Y -4.4%
INDV
INDV • United States
Indivior Pharmaceuticals, Inc.
35.83 USD
4.23B USD 1Y +47.3%
000963.SZ
000963.SZ • China
HD MEDICINE
27.29 CNY
7.16B USD 1Y -34.6%
LNTH
LNTH • United States
Lantheus Holdings, Inc.
100.15 USD
6.54B USD 1Y +87%
VTRS
VTRS • United States
Viatris Inc.
17.64 USD
20.26B USD 1Y +74.9%
RGC
RGC • Hong Kong SAR China
Regencell Bioscience Holdings L
7.35 USD
3.64B USD 1Y -60.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
84.3% p.a.
Max Drawdown (5Y)
-78.9%
Sharpe Ratio (5Y)
0.33
Beta Factor
2.43
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 477%.
Unprofitable business model: The company is currently generating net losses.
High market risk: Beta of 2.43 indicates above-average volatility compared to the broader market.
Elevated Short-Term Volatility: 3Y volatility (94.9%) is noticeably higher than the 5Y average (84.3%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (84.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -78.9% in the extended horizon.
ende